Spending investment dollars on compliance can limit R&D and delay R&D so changes like the on-ramp, Congressman Fitzpatrick's legislation, and Congressman Hurt's audit firm rotation bill are important for growing biotechs without product revenue.
Emphasizing the importance of legislative changes for biotech R&D funding.
Share
More from Michael Fitzpatrick
I care deeply about the retail investor and the low- and moderate-income investor.
Government is too big; government is too opaque; and government is increasingly unaccountable to Congress.
This deal, in my opinion, is going to lead to war. And it will make war more likely.
How is it the rating agencies get to pick and choose what debt they are going to rate and what debt they are not going to rate, especially when it affects small investors in the United States of America?
Other voices in this conversation
